Pulnovo Medical Announces Results of PADN-HF-PH Trial
Pulnovo Medical has presented the results of the PADN-HF-PH trial. The clinical findings demonstrated a 51% reduction in the risk of clinical worsening for patients with PH-LHD.
Pulnovo Medical announced the results of its PADN-HF-PH trial at the ESC Congress 2026. The findings were simultaneously published in The New England Journal of Medicine (NEJM).
The clinical study involved 264 patients diagnosed with pulmonary hypertension due to left heart disease (PH-LHD). The results showed a 51% reduction in the risk of clinical worsening for these patients.
The trial aimed to assess the efficacy and safety of Pulnovo Medical's device. The positive outcomes suggest a potential new treatment avenue for individuals suffering from this condition, where treatment options have previously been limited.
Pulnovo Medical is proceeding with further analysis of the data and is planning subsequent steps for the device's market introduction to improve patient access worldwide.